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there was an estimated 480,000 cases resistant to key first line drug rifampicin (RIF) and isoniazid (INH) (multi drug resistant (MDR) TB), of whom approximately 9.7% had additional resistance to fluoroquinolones and aminoglycosides (extensively drug resistant (XDR) TB) [2] . TB treatment is believed to follow a biphasic response to chemotherapy with the majority of bacilli being rapidly killed early on in the bactericidal phase whilst the sterilising phase slowly results in eradication of persisting MTB to reduce risk of relapse. These subpopulations may be anatomically sequestrated and thereby escape immune surveillance and drug penetration. Currently endorsed treatment regimens vary in duration between 6 months in drug susceptible (DS)-TB to 24 months in drug resistant (DR)-TB. Although treatment success rates in DS TB are generally close to 90% [2] , in drug resistant TB they are below 50% [3] .
Standardized definitions of treatment response and outcomes enable optimal surveillance and valid comparisons across settings (Table 1) .
Priorities in assessment of response to treatment include both identification and prediction of treatment induced adverse events such as drug side effects and paradoxical reactions, temporary and permanent disability secondary to disease, treatment failure and subsequent relapse. Assessment of treatment response on an individualized and programmatic basis in both adults and children is predominantly based on clinical, radiological and bacteriological measures.
Clinical assessments include overall performance status, weight gain during treatment and resolution of systemic and organ based symptoms. Radiological assessments include use of plain film radiograph to assess resolution of pathology and to diagnosis of paradoxical reactions. Computed tomography (CT) and/or magnetic resonance imaging are also utilized in certain cases if clinically indicated and within available resource. Bacteriological assessment includes smear and or culture conversion at various intervals depending on whether treating DS-or DR-TB [4] . Blood tests such as C-reactive protein (CRP) can be done at baseline and during treatment to monitor clinical improvement.
Monitoring of liver enzymes pre-treatment is indicated in those with risk of premorbid liver disorder and should be monitored, along with all patients symptomatic of drug induced liver injury [5] . In some settings, therapeutic drug monitoring is used [6] .
When conducting research, priorities in assessment of treatment response are to identify predictors of long-term outcomes, quantify efficacy of agents in the context of multidrug therapy, and to ascertain non-inferiority of treatmentshortening regimens. In TB, adequate powering of studies, and lengthy follow up times are required to reliably predict long term unfavourable outcomes, which is expensive and logistically challenging. For this reason, biomarkers and correlate endpoints predicting long-term outcomes are desirable [7] . Changes induced by a therapy on a correlate should reliably reflect changes in the long-term treatment outcome [8] . We will review evidence of host and pathogen based biomarkers of long-term treatment response in latent and active TB and outline key considerations for future research.
PATHOGEN BASED MODELS AND BIOMARKERS

Hollow fiber system model
The hollow fiber bioreactor system can be used as an in vitro pharmacokineticpharmacodynamic (PK-PD) model of TB [9] . It has been used to assess early bactericidal activity and recreate realistic PK patterns of single and multi-drug exposure. It can predict PK/PD exposures associated with development of drug resistance. In tandem with Monte Carlo simulations, it can also predict impact of dose titration and dosing schedules. It can be adapted to reproduce environmental conditions of persistence models to study pharmacodynamics of sterilizing activity [9] . However, it does not model the host immune response, differential spatial distribution in diseased tissue nor the impact of clinical strain variation. Results need to be validated in adequately powered, appropriately controlled clinical studies. Limitations in methodology include variability between different centers and intraindividual variation pre-treatment [12] . Patients must be able to expectorate good volumes of sputum. There may be loss of viable CFUs cultured if sputum is decontaminated with sodium hydroxide treatment. There is some evidence to suggest type of culture media and growth factors/inhibitors [13] influence growth of different populations of MTB during chemotherapy [14] .
Sputum based assays (summarized in
2) 2-month sputum culture conversion and time to culture conversion as intermediate bacteriological endpoints
In a meta-analysis Wallis et al found a relationship between 2-month culture status on solid media and relapse rate that was consistent across regions [15] .
There was significant correlation between 2-month (Hong Kong) and 3-month (Africa) culture status and combined rate of failure, relapse and death [16] .
Johnson et al showed that treatment shortening from 6 months to 4 months in patients with both non-cavitatory pulmonary disease and culture negative status at 2 months was associated with a significantly increased risk of relapse compared with a standard 6 month regimen [17] . These findings were also supported by another retrospective analysis [18] . Despite Phase 2 studies demonstrating higher rates of negative 2-month sputum cultures and earlier time to culture conversion when compared to standard 6-month control regimens [19, 20] , four phase 3 treatment shortening trials involving fluoroquinolones [21] [22] [23] [24] failed to show non-inferiority of treatment shortening. This apparent lack of correlation between sputum conversion and treatment outcome is thought to be due bacterial persistence and incomplete sterilization by 4-month fluoroquinolone regimens. Using meta-regression modeling, Wallis et al showed that 2-month sputum conversion and treatment duration could independently predict relapse [25] . This model also predicted that, given the treatment duration of aforementioned trials, there would be unacceptable relapse rates as clinical outcome [25] . The predictive value of 2-month sputum conversion was maintained despite incorporation of data from the fluoroquinolone trials [26] . 
5) Whole blood bactericidal assay
Growth of clinical MTB isolates in ex vivo whole blood culture taken at selected time points during therapy is a potential biomarker of sterilizing activity, encompassing both strain variation and host effector immune mechanisms. In one study, whole blood bactericidal activity correlated with rate of fall in sputum In latent TB, Young et al. found 6 mycobacterial proteins that were present in urine of HIV uninfected patients which suggests that products other than LAM may be useful for measuring bacterial load over a wide dynamic range, but these require verification in longitudinal studies [46] .
HOST BASED BIOMARKERS
Lung function testing
Most active pulmonary TB patients exhibit a combined obstructive/restrictive pattern of lung function impairment, however the restrictive impairment pattern haemoglobin, and exercise tolerance as measured by the 6-minute walk test (p<0.02 for all correlates other than smear grade). The score had initially been developed and validated in an Indonesian population that was mostly HIV-1 uninfected, however in an unrelated cohort from Cameroon with 30% HIV-1 coinfection the score also predicted sputum non-conversion at two months with similar specificity and sensitivity, albeit by using a lower cut-off value [52] .
Although there was poor inter-reader agreement in the initial study by Ralph et al.
(prevalence and bias adjusted kappa: 0.37 for cavitation, 0.31 for patchy consolidation and 0.7 for confluent consolidation), a recent publication from South Africa showed greater agreement (kappa value for cavitation: 0.66, overall inter-reader correlation: r=0.86, p<0.001) in using the Timika score [53] . The latter study however found an optimal score cut-off of 61.3, which could only predict 2 month sputum smear status with a sensitivity of 74.1% (95%CI 65.0 to 81.9) and a specificity of 57.7% (95%CI 51.7 to 63.6). Utility in predicting long term outcomes of failure and relapse by month 30 was limited by suboptimal sensitivity and specificity of 67% and 57% respectively. The persistance of one or more cavity on chest radiograph after treatment completion may have prognostic value. Indeed it was found that patients with a persistent cavity on their end of treatment CXR had more than twice the risk for TB relapse when compared to those with resolved cavities [54] .
2) Ultrasound
Particularly in the context of asymptomatic disease, ultrasound (US) represents an imaging modality with reliable detection capabilities that may be utilized by the clinician and researcher alike. The commonest radiographic finding in pulmonary TB in children is mediastinal lymphadenopathy, which may be readily detected by US. US detection of mediastinal lymphadenopathy was comparable to CT and had superior sensitivity to chest x-ray [55] . With regard to peritoneal TB, US may be useful for follow-up, having confirmed the diagnosis by more specific means, but there are currently relatively few studies supporting this [58, 59] . Further studies at earlier time points, with larger numbers and in different age groups and degrees of immunosuppression are warranted. the reduction in sputum bacillary load observed in treatment responsive patients [63] and return to normal of initially elevated CRP concentrations may correlate with therapeutic response [64] . Conversely, pre-treatment concentrations above 20mg/l which persisted during treatment was associated with adverse treatment outcomes in one small study [65] . Procalcitonin (PCT) levels are rarely significantly elevated in tuberculosis, so much so that it is often used to differentiate acutely between pulmonary TB and pneumonia, where the latter often exhibit elevated levels of PCT. The exception being in cases of severe and disseminated TB, where PCT levels equal or in excess of 0.5 ng/ml is indicative of poor prognosis and increased mortality risk [66] .
3) Combined
2) Cytokines and T lymphocyte subsets
Despite the wide variability and often contrasting findings observed in the review by Clifford et al. [67] , it was found that the majority of studies evaluating both TB- pulmonary and extrapulmonary TB [75] . This is a potential biomarker in sputumsparse and smear negative individuals [75] . However, there is variation in T reg responses during chemotherapy in different studies. Differential human leukocyte antigen (HLA) expression in different populations may explain this variation [75] .
A recent study also showed that MTB-specific T cell expression of activation status as measured by HLA-DR and CD38, along with the intracellular proliferation marker Ki-67 correlates with both bacillary burden and subsequent sputum conversion [76] , but these findings need to be validated in larger prospective studies.
Urokinase-type plasminogen activator receptor is expressed by immune cells in response to bacterial phospholipases and pro-inflammatory cytokines. Rabna et al. showed that high plasma levels of soluble urokinase plasminogen activator receptor (suPAR) at inclusion, or at any point during treatment was associated with increased mortality. An increase in suPAR after 1 month, compared with diagnosis, was associated with a Mortality Rate Ratio (MRR) of 4.5 (95%CI:
1.45-14.1) during the remaining 7 month treatment period. However, this study did not identify a threshold to define 'high suPAR' levels but specified that levels below 3.5ng/ml were associated with low mortality [77] .
3) Tissue destruction and remodeling markers
There is interest in the matrix metalloproteinases (MMPs) in the setting of TB biomarker research. The MMPs constitute a group of endopeptidases secreted by a variety of host cells in response to TB-related MMP upregulation and in so doing affects enzymatic degradation of extra-cellular matrix proteins which may play a crucial role in cavity formation [78] . Numerous MMPs, most notably MMP-1 and MMP-3, have been found to be increased in patients with active pulmonary TB [79] , independently associated with higher TB severity scores [80] and undergo rapid decline during treatment [78] . MMP-1, -3 and -8 concentrations in sputum has also been found to decline in response to successful ATT [81] .
Delayed sputum culture conversion was associated with increased MMP-1 levels [82] . Elevated MMP-9 levels have been associated with TB meningitis, with treatment related decline in concentrations being apparent in one small study [83] . Thus, MMPs represent an attractive possibility as TB biomarkers, given the potential of recognition of phenotypically distinct clinical presentations of TB perhaps in conjunction with other TB biomarkers such as heme-oxygenase 1 [84] .
Transcriptomic profiling
TB is characterized by an interferon-inducible neutrophil-driven peripheral blood transcriptional signature [85] . Several studies have documented this signature relates to disease extent and shows reversion during successful therapy towards that of latently infected control participants, with the most profound changes occurring within the first weeks of treatment [85] , [86] . Cliff et al. showed downregulation of complement and interferon-related genes involved in the inflammatory response after 1 week. There was a slower up-regulation of lymphocyte components, including B-and T-lymphocyte-related genes between weeks 4 and 26 of ATT [87] . Participants experiencing subsequent relapse showed significant up-regulation of cytotoxic cell-mediated killing in response to MTB in vitro both at baseline and up to 4 weeks of ATT [88] . Thus, there is the potential of transcriptomic profiling to aide both research on novel tuberculosis treatments and to monitor therapy. However studies of greater power and with adverse outcomes are required to benchmark this promising technique better.
Interferon-gamma release assays (IGRA)
The antigen specific release of interferon-gamma in response to MTB antigens in vitro has become an accepted alternative to the tuberculin skin test when determining immune sensitization. It is also well recognised that change in the response to tuberculosis antigens in vitro occurs during ATT [89] . However a recent systematic review on the use of IGRA for treatment monitoring concluded that whilst the response tended to fall during treatment, there was a large degree of individual variation and thus IGRA were not felt useful in this respect [90] . A number of experimental studies have also documented clear changes in antigen specific interferon-gamma release during the course of treatment for latent tuberculosis [91] , [92] , [93] . However the absence of a 'gold standard' for the diagnosis of latent tuberculosis confounds interpretation and large-scale studies with clinical endpoints have not been performed. Cohorts from diverse epidemiological settings and representing the full spectrum of paediatric TB should be followed up longitudinally in a standardized manner to create biorepositories enabling development of biomarkers for treatment monitoring in paediatric TB [94] .
EXPERT COMMENTARY
To date, there is a deficit of studies addressing potential biomarkers to predict treatment failure and relapse in DR-TB. This is a research priority to be addressed in both prospective cohorts and randomised controlled trials assessing efficacy of new DR-TB regimens. Such biomarkers/surrogate endpoints will hopefully expedite regulatory approval of new drugs [95] . 
FIVE YEAR VIEW
Ultimately, establishing reliable evidence-based measures of monitoring treatment of TB will require a deeper understanding of pathogenesis, including both host and mycobacterial factors.
Novel technologies and integrated use of transcriptomic/proteomic/metabolomic approaches may enhance treatment monitoring, particularly of special treatment groups such as paediatric and extrapulmonary TB. Developing mass spectrometry-based technologies as well as novel biosensors and "antigen capture" techniques such as aptamers are also likely to be investigated.
A preliminary study by Nahid et al used a multiplexed aptamer-based proteomic technology to define a non-culture based 5-marker signature predictive of 2-month culture status. This approach shows promise and should be validated in larger cohorts [97] . The diversity of the MTB secretome and the distinctive MTBassociated cell wall lipids provide an attractive option for future sputum antigen based tests. A limitation of these respiratory assays is that they are restricted to populations of bacilli that are able to access the airways. Rapid clearance of bacteria from the sputum is highly desirable and essential, but achievement of this status does not guarantee avoidance of relapse.
An objective of future research is to enhance understanding of posttranscriptional and post-translational regulation of cytokines/chemokines and their role in host-pathogen immune response.
Future research objectives also include advancing knowledge of how lung and sputum microbiome affects MTB response during chemotherapy. Genetic [98]  Interplay between the spatio-temporal distribution of drugs at the disease site, bacillary sub-populations of varying levels of drug susceptiblity and interactions with the host immune microenvironment may be studied via a multi-systems approach. These assays are not applicable to AFB negative sputa. Serial samples taken longitudinally during treatment are required for assessment and a single sample e.g. pre-treatment has limited utility.
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[28, 36, 37] Whole blood bactericidal activity Inferior bactericidal activity seen in whole blood cultures of sputa taken from patients at an interim time point in treatment may predict delayed sputum sterilization/subsequent relapse The assay may be influenced by factors unrelated to outcome e.g. sputum volume and viscosity. This is a culture based technique and can take several weeks. [40, 41] Abbreviations: AFB acid fast bacilli, CFU colony forming unit, DNA deoxyribonucleic acid, RNA ribonucleic acid, DS drug sensitive, DR drug resistant, TB tuberculosis, PK pharmacokinetics, SOP standard operating procedure. -High plasma levels of suPAR at inclusion or at any point during treatment was associated with increased mortality.
-No specific thresholds specified -No specific thresholds specified and not specific to tuberculosis [70] [71] [72] [73] [74] 76] [77] matrix metalloproteinases (MMPs)
MMP-1, -3 and -8 concentrations in sputum decline in response to successful ATT and delayed culture conversion is positively correlated with MMP-1.
Variation in production, regulation and biological activity of MMPs in relation to different points in disease pathogenesis. Significant ethnic heterogeneity in MMP profile during anti-tuberculosis therapy
